Pearl Therapeutics, Inc.

Bayer Intellectual Property Gmbh

Novartis Ag

Nektar Therapeutics

Pearl Thereapeutics, Inc.

Sarvajna Kumar Dwivedi

Reinhard Vehring

Adrian Edward Smith

Michael Steven Hartman

Vidya B Joshi

David Lechuga-Ballesteros

Chatan Charan

Michael L King

Matthew S Ferriter

Jill Sherwood

Fred Hamlin

Denny Himel

Robert V Sheehy, Jr

Dan Deaton

Brian Foster

Thomas E Tarara

William W Alston

Michael A Eldon

Danforth Miller

Herman E Snyder

Keith Washco

Sarma Duddu

Srinivas Palakodaty

Theresa D Sweeney

Richard Malcolmson

Trixie Tan

Alan Kugler

Ali Kazmi

Jason H Speck

James Ivey

Christopher Frantz

Guy V Tucker

Gerard Libby

Vipul Negi

Kyle Woodard

Robert V Sheehy

Systems and methods for isolating and/or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.

Drug delivery systems and related methods

Methods and systems for the preparation of conditioned micronized active agents. Additionally, methods and systems for in-process conditioning of micronized active agent particles and compositions comprising conditioned micronized materials.

Methods and systems for conditioning of particulate crystalline materials

Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting &#x3b2;adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems

An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25&#xb0; C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.

Antibiotic formulations, unit doses, kits, and methods

Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems

Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Compositions, methods and systems for respiratory delivery of two or more active agents

Antibiotic formulations, unit doses, kits and methods

[object Object]

An aerosol introducer is provided for introducing an aerosolized pharmaceutical formulation into a ventilator circuit. The ventilator circuit comprises an endotracheal tube, an inhalation line extending from a ventilator, and an exhalation line extending from the ventilator. The aerosol introducer comprises a first end connectable to the inhalation line and the exhalation line; a second end connectable to the endotracheal tube; a first channel extending from the first end to the second end; a second channel extending from the first end to the second end; an inlet in the first channel, the inlet being adapted to receive an aerosolized pharmaceutical formulation; and a valving mechanism comprising one or more valves that reduce the loss of aerosolized pharmaceutical formulation to the exhalation line.

Introducing aerosol into a ventilator

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 &#x3bc;m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.

Compositions comprising amphotericin B, methods, and systems

Growing community of inventors

Redwood City, CA, United States of America

Sarvajna Kumar Dwivedi